AI-Based Predictive Analytics Platform Receives FDA Emergency Use Authorization in Support of COVID-19 Patients

CLEW-ICU, a new ICU solution, has become the only device to receive FDA Emergency Use Authorization (EUA) for providing early identification of patients who are likely to experience respiratory failure or hemodynamic instability, both potentially common but significant complications associated with COVID-19.

Developed by CLEW (Netanya, Israel), CLEW-ICU allows healthcare providers to use predictive screening information to help identify patients with an increased likelihood of being diagnosed with respiratory failure or hemodynamic instability. The AI-based algorithms are machine-learning models trained to identify respiratory failure and or hemodynamic instability hours in advance. This allows for additional evaluation and potentially early intervention, planning, resource management.

CLEW’s AI models have been trained on nearly 100,000 patients in the ICUs, and scales to cope with patient volume surges while reducing a caregiver’s exposure risk to infected patients. CLEW’s models were developed and intended for both local ICUs and TeleICUs and integrates best practice modules. The streamlined at-a-glance web application is designed for near real-time access to patient data and provides tools for both worklist, unit and multiunit views, featuring unit occupancy and patient risk level. CLEW-ICU integrates caregiving of local and remote teams enabling workflow and resource decision making.

“Healthcare providers need more than simple analytics. Systems need to integrate into the provider’s workflow, offering ease of use and actionable data. The CLEW-ICU platform is designed to enable healthcare providers to monitor patient predicted risk levels across all units in real-time allowing for smart decision making about clinical resource allocation, ensuring prompt, proactive and efficient patient care” said Gal Salomon, CLEW CEO.

Related Links:
CLEW